Bonterra Resources Inc. is a Canadian gold exploration company focused on acquiring, exploring, and evaluating mineral properties primarily in Quebec. The company has a diverse portfolio that includes key projects such as the Gladiator Deposit, the Moroy Deposit, and the Barry Deposit, all situated within the mining-friendly Abitibi Greenstone Belt. Bonterra also controls the only permitted gold mill in the region, supporting its operations and exploration efforts. With a substantial land position of approximately 35,000 hectares in the Urban Barry Camp, Bonterra is well-positioned to capitalize on gold exploration opportunities. Incorporated in 2007 and headquartered in Val-d'Or, Bonterra emphasizes its commitment to exploring gold deposits within its extensive mineral rights.
Viseon, Inc. is a medical device company based in Irvine, California, focused on developing innovative technology for Minimally Invasive Spine Surgery (MISS) procedures. Founded in 2017 as a spin-out from Rebound Therapeutics Corporation, Viseon has created the Voyant technology, which serves as a single-use disposable alternative to traditional surgical microscopes, endoscopes, and loupes. This technology enables the operative field to be projected onto a high-definition flat panel display, benefiting both the operating room and remote locations. The company has made significant strides in recent months, developing a range of devices aimed at enhancing procedural and clinical outcomes in spine surgery. Viseon has established a robust intellectual property portfolio with 13 patents and formed a Scientific Advisory Board composed of leading MISS physicians. Additionally, it has completed a series of pre-clinical studies in preparation for initial human-use trials.
AZTherapies, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing innovative treatments for neurodegenerative diseases such as Alzheimer’s, stroke, ALS, and Parkinson’s. Founded in 2011, the company is in the advanced clinical stage with a pipeline that includes its lead candidate, ALZT-OP1. This candidate employs a multi-modal approach targeting neuroinflammation, which is recognized as a key factor in neurodegeneration. The ongoing Phase 3 COGNITE trial, which focuses on early Alzheimer's disease, has been fully enrolled and is set to conclude soon. In addition to Alzheimer's, AZTherapies is also working on therapies for cognitive impairment following stroke, ALS, and other related conditions, aiming to enhance cognitive function and quality of life for patients facing limited treatment options.
Specialty Renal Products, a subsidiary of Nephros, is focused on the development of medical device products for patients with renal disease, including a hemodiafiltration system for the treatment of patients with ESRD.SRP intends to develop and market a filtration system for use in conjunction with the disposable tubing circuit sets used in treatments that provide continuous renal replacement therapy (CRRT). The system will apply to patients who present in the intensive care unit with acute kidney injury (AKI). CRRT allows the clinician the ability to manage unstable AKI patients by offering slower ultrafiltration and solute removal. Some advantages with performing CRRT continuously (24 hours per day) include improved hemodynamic tolerance and more control over the total volumes given and removed from unstable AKI patients.
Viseon, Inc. is a medical device company based in Irvine, California, focused on developing innovative technology for Minimally Invasive Spine Surgery (MISS) procedures. Founded in 2017 as a spin-out from Rebound Therapeutics Corporation, Viseon has created the Voyant technology, which serves as a single-use disposable alternative to traditional surgical microscopes, endoscopes, and loupes. This technology enables the operative field to be projected onto a high-definition flat panel display, benefiting both the operating room and remote locations. The company has made significant strides in recent months, developing a range of devices aimed at enhancing procedural and clinical outcomes in spine surgery. Viseon has established a robust intellectual property portfolio with 13 patents and formed a Scientific Advisory Board composed of leading MISS physicians. Additionally, it has completed a series of pre-clinical studies in preparation for initial human-use trials.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Rebound Therapeutics Corp. focuses on developing single-use, disposable medical devices designed for access, imaging, and illumination in minimally invasive surgical procedures. Established in 2015 and based in Irvine, California, the company has made significant strides in product development over a short period, creating a unique range of devices aimed at enhancing procedural and clinical outcomes. Rebound has also formed a Scientific Advisory Board comprised of leading physicians in minimally invasive surgery and has secured 14 patents to protect its intellectual property. The company has completed pre-clinical studies that support its transition to initial human use, which is scheduled to commence soon. As of September 2019, Rebound Therapeutics operates as a subsidiary of Integra LifeSciences Holdings Corporation.
ElMindA Ltd. focuses on developing diagnostic and treatment tools for brain-related disorders through its innovative Brain Network Activation (BNA) technology. This platform integrates electroencephalography and event-related potential testing with machine learning and advanced algorithms to visualize and assess the brain's neural networks. By capturing electrophysiological patterns related to specific cognitive tasks, ElMindA creates high-resolution, three-dimensional representations of functional neural pathways, which can inform the understanding of various brain functions, including sensory processing, attention, and memory. The technology has applications in conditions such as mild traumatic brain injury, major depressive disorder, Parkinson's disease, and ADHD, aiming to enhance clinical practices in neuroscience. Founded in 2006, ElMindA operates from Herzliya, Israel, with an additional office in Glenview, Illinois.
Vantage Sports, Inc. is a data and video analytics company that specializes in providing an advanced platform for analyzing player performance in sports. Founded in 2011 and based in Bellevue, Washington, the company offers a comprehensive data collection service that goes beyond traditional statistics, enabling sports teams, media, and fans to gather and utilize in-depth performance metrics. Vantage Sports aims to transform the sports data landscape by delivering extensive analytical tools that enhance the understanding of athletes and franchises, particularly in basketball. The company operates as a subsidiary of Competitive Analytics Consulting LLC.
DIG operates a restaurant chain focused on providing fresh, locally sourced meals. With an emphasis on seasonal ingredients, the restaurants offer organic dishes prepared from scratch using vegetables, whole grains, and naturally-raised meats. The company collaborates closely with trusted farmers and producers to ensure high-quality ingredients. Customers can enjoy healthy, expertly crafted meals at an affordable average price, with the convenience of online ordering and direct table service.
Private Equity Round in 2013
OptiScan Biomedical Corporation develops glucose monitoring systems for the intensive care unit (ICU)/CCU. It offers OptiScanner, an automated, bedside glucose monitoring system to assist healthcare providers manage the glucose level of critically ill patients. The company’s OptiScanner provides serial blood glucose measurements for a range of glucose concentrations. OptiScan Biomedical Corporation was founded in 1994 and is based in Hayward, California.
Sophono, Inc. is a medical device manufacturer based in Boulder, Colorado, specializing in implantable magnetic bone conduction hearing devices. Founded in 2009, the company focuses on providing solutions for individuals with conductive hearing loss, mixed hearing loss, and single-sided deafness. Its flagship product, the Alpha 2 MPO, offers an abutment-free experience, allowing the device to be placed under the skin while using magnets for external sound processing. Sophono distributes its products primarily through clinics, aiming to improve the quality of life for patients suffering from severe to profound hearing impairment. In 2015, the company became a subsidiary of Medtronic plc, further enhancing its capabilities in the medical device sector.
Invuity, Inc. is a medical technology company specializing in the development and marketing of illuminated surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable devices that enhance visibility during surgeries. Its product offerings include various illuminated retractor systems and handheld illuminators designed for a range of surgical applications, including breast, orthopedic, spine, cardiothoracic, and gynecological procedures. The BriteField Port System and BriteField McCulloch retractor are notable products that facilitate illumination and visualization during minimally invasive surgeries. Invuity sells its devices through a network of direct sales representatives and independent agents, as well as directly to hospitals and surgeons. Founded in 2004 and headquartered in San Francisco, California, Invuity was previously known as Spotlight Surgical, Inc. and has been operating as a subsidiary of Stryker Corporation since 2018.
Invuity, Inc. is a medical technology company specializing in the development and marketing of illuminated surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable devices that enhance visibility during surgeries. Its product offerings include various illuminated retractor systems and handheld illuminators designed for a range of surgical applications, including breast, orthopedic, spine, cardiothoracic, and gynecological procedures. The BriteField Port System and BriteField McCulloch retractor are notable products that facilitate illumination and visualization during minimally invasive surgeries. Invuity sells its devices through a network of direct sales representatives and independent agents, as well as directly to hospitals and surgeons. Founded in 2004 and headquartered in San Francisco, California, Invuity was previously known as Spotlight Surgical, Inc. and has been operating as a subsidiary of Stryker Corporation since 2018.
Ellipse Technologies is focused on developing its implantable remote control technology platforms to include innovative treatments for a broad spectrum of spinal and orthopedic deformity applications, orthopedic trauma and fracture management. The initial products restore proper anatomic position and alignment of the spine and long-bones. MAGECâ„¢ MAGnetic Expansion Control System utilizes a novel motion-preserving, minimally-invasive technology that, through communication with an external magnetic field, can be non-invasively adjusted in an outpatient setting via remote control by the physician to correct spinal deformities. PRECICE System uses non-invasive adjustable intramedullary rods or bone plates to treat long-bone abnormalities, often the result of acute or chronic fractures. Ellipse is a privately-held medical device company located in California.
Reverse Medical is a commercial-stage medical device company focused on revascularizing patients experiencing Acute Ischemic Stroke.
International Battery (IB) is a green technology company providing environmentally friendly, large format, rechargeable lithium-ion cells and batteries – designed, developed and manufactured in the USA. IB provides next generation cell chemistries, electronics and advanced packaging technologies, broad design experience, and offers total solutions for rechargeable battery applications. There batteries can be used in a wide range of vehicular, industrial and military applications.
Infinia Corporation is a solar energy technology company that specializes in the development of innovative power generation systems. The company's flagship product, the PowerDish, is a proprietary solar power generation device that efficiently converts solar energy into electricity. Infinia also provides micro combined heat and power systems targeted at residential energy consumers, as well as solar and biomass-powered electric generators designed for various applications, including deep space missions and remote power needs. The PowerDish is aimed at energy asset developers, utilities, and commercial companies involved in large-scale solar projects, with a global launch anticipated to have begun in late 2010.
Infinia Corporation is a solar energy technology company that specializes in the development of innovative power generation systems. The company's flagship product, the PowerDish, is a proprietary solar power generation device that efficiently converts solar energy into electricity. Infinia also provides micro combined heat and power systems targeted at residential energy consumers, as well as solar and biomass-powered electric generators designed for various applications, including deep space missions and remote power needs. The PowerDish is aimed at energy asset developers, utilities, and commercial companies involved in large-scale solar projects, with a global launch anticipated to have begun in late 2010.
GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.
Interventional Spine, Inc. engages in the design, development, production, and distribution of implantable devices for the spine to patients, surgeons, and hospitals worldwide. It offers Opticage expandable interbody fusion device; and PERPOS PLS System compressible facet fixation system. The company provides devices for podiatric and orthopedic trauma markets; and sells its products through a network of distributors. The company was formerly known as Triage Medical, Inc. and changed its name to Interventional Spine, Inc. in November 2006. Interventional Spine, Inc. was founded in 2000 and is based in Irvine, California. As of January 3, 2017, Interventional Spine, Inc. operates as a subsidiary of DePuy Synthes, Inc.
Epiphany Biosciences, Inc. is a privately-held company based in San Francisco, California, focused on developing therapeutic products and diagnostic technologies to combat pathogenic viruses. The company specializes in creating antiviral therapeutics aimed at preventing the spread of viruses such as varicella zoster virus, Epstein-Barr virus, and hepatitis C virus. To advance its mission, Epiphany has assembled a team of experts in virology, clinical practice, and drug development, leveraging their extensive experience in the pharmaceutical industry. Through its innovative small molecule therapeutics platform, Epiphany aims to address significant public health challenges associated with viral infections.
ICx Technologies is a leader in the development and integration of advanced sensor technologies for homeland security, force protection and commercial applications. Their proprietary sensors detect and identify chemical, biological, radiological, nuclear and explosive threats, and deliver superior awareness and actionable intelligence for wide-area surveillance, intrusion detection and facility security. They then leverage their unparalleled technical expertise and government funding to address other emerging challenges of their time ranging from a cleaner environment, alternative energy to life science.
Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.
Private Equity Round in 2005
Javelin Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products for the pain management market primarily in the United States and Europe. Its products focus on treating various pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain (orthopedic injury pain), procedural pain, and burn pain. The company's Dyloject (injectable diclofenac) received approval for marketing to treat post-operative pain in the United Kingdom and was licensed to Therabel Pharma N.V. for commercialization in the European Union and certain other countries outside the United States. Its products in the Phase 3 development stage in the U.S. include Dyloject (diclofenac sodium injectable), an injectable formulation of diclofenac and a prescription nonsteroidal anti-inflammatory drug that is used to treat post-operative pain due to its combination of effectiveness and tolerability; Ereska (intranasal ketamine), a proprietary nasal formulation; and Rylomine (intranasal morphine) for treatment of acute moderate-to-severe pain, including breakthrough pain. Javelin Pharmaceuticals has license agreements with Shimoda Biotech, Ltd. to develop and commercialize products related to a proprietary formulation of the injectable delivery of diclofenac; and West Pharmaceutical Services, Inc. to develop and commercialize intranasal morphine for the transmucosal delivery of morphine to humans and animals for the treatment of pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.
Encorp is a provider of network technology and infrastructure management services focused on the distributed energy market. The company specializes in energy automation software and grid-interconnection equipment that facilitate the control of various power resources, including engine-generator sets, microturbines, fuel cells, combined heat and power systems, and energy storage devices. By harnessing its advanced Gold Box technology, Encorp enables federal, institutional, and commercial clients to enhance energy savings, security, and efficiency. Its solutions aim to transform the electric grid into a cleaner, more cost-effective, and resilient system. This integration of diverse energy resources is essential for enterprises requiring high-quality, reliable power at predictable costs, while also contributing to the reduction of carbon emissions.
NxtPhase develops, manufactures, and markets optical sensor and digital solutions for the electric power industry. The company’s products include optical current and voltage sensors; and opto-electronic modules that provide signal processing electronics for voltage and current transducers. NxtPhase was founded in 1993 and is headquartered in Vancouver, Canada.